Removal of endobronchial malignant mass by cryotherapy improved performance status to receive chemotherapy

Yueh Fu Fang, Meng Heng Hsieh, Tsai Yu Wang, Horng Chyuan Lin, Chih Teng Yu, Chun Liang Chou, Shu Min Lin, Chih Hsi Kuo, Fu Tsai Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although malignant endobronchial mass (MEM) has poor prognosis, cryotherapy is reportedly a palliative treatment. Clinical data on postcryotherapy MEM patients in a university-affiliated hospital between 2007 and 2011 were evaluated. Survival curve with or without postcryotherapy chemotherapy and performance status (PS) improvement of these subjects were analyzed using the Kaplan-Meier method. There were 59 patients (42 males), with median age of 64 years (range, 51-76, and median performance status of 2 (interquartile range [IQR], 2-3). Postcryotherapy complications included minor bleeding (n=12) and need for multiple procedures (n=10), while outcomes were relief of symptoms (n=51), improved PS (n=45), and ability to receive chemotherapy (n=40). The survival of patients with chemotherapy postcryotherapy was longer than that of patients without such chemotherapy (median, 534 versus 106 days; log-rank test, P=0.007; hazard ratio, 0.25; 95% confidence interval, 0.10-0.69). The survival of patients with PS improvement postcryotherapy was longer than that of patients without PS improvement (median, 406 versus 106 days; log-rank test, P=0.02; hazard ratio, 0.28; 95% confidence interval, 0.10-0.81). Cryotherapy is a feasible treatment for MEM. With better PS after cryotherapy, further chemotherapy becomes possible for patients to improve survival when MEM caused dyspnea and poor PS.

Original languageEnglish
Article number369739
JournalScientific World Journal
Volume2014
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Cryotherapy
chemotherapy
Chemotherapy
Drug Therapy
confidence interval
Survival
Hazards
hazard
Confidence Intervals
relief
removal
Palliative Care
Dyspnea
Hemorrhage

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)

Cite this

Removal of endobronchial malignant mass by cryotherapy improved performance status to receive chemotherapy. / Fang, Yueh Fu; Hsieh, Meng Heng; Wang, Tsai Yu; Lin, Horng Chyuan; Yu, Chih Teng; Chou, Chun Liang; Lin, Shu Min; Kuo, Chih Hsi; Chung, Fu Tsai.

In: Scientific World Journal, Vol. 2014, 369739, 01.01.2014.

Research output: Contribution to journalArticle

Fang, Yueh Fu ; Hsieh, Meng Heng ; Wang, Tsai Yu ; Lin, Horng Chyuan ; Yu, Chih Teng ; Chou, Chun Liang ; Lin, Shu Min ; Kuo, Chih Hsi ; Chung, Fu Tsai. / Removal of endobronchial malignant mass by cryotherapy improved performance status to receive chemotherapy. In: Scientific World Journal. 2014 ; Vol. 2014.
@article{71324239416f4e09bf4a1f30249c7812,
title = "Removal of endobronchial malignant mass by cryotherapy improved performance status to receive chemotherapy",
abstract = "Although malignant endobronchial mass (MEM) has poor prognosis, cryotherapy is reportedly a palliative treatment. Clinical data on postcryotherapy MEM patients in a university-affiliated hospital between 2007 and 2011 were evaluated. Survival curve with or without postcryotherapy chemotherapy and performance status (PS) improvement of these subjects were analyzed using the Kaplan-Meier method. There were 59 patients (42 males), with median age of 64 years (range, 51-76, and median performance status of 2 (interquartile range [IQR], 2-3). Postcryotherapy complications included minor bleeding (n=12) and need for multiple procedures (n=10), while outcomes were relief of symptoms (n=51), improved PS (n=45), and ability to receive chemotherapy (n=40). The survival of patients with chemotherapy postcryotherapy was longer than that of patients without such chemotherapy (median, 534 versus 106 days; log-rank test, P=0.007; hazard ratio, 0.25; 95{\%} confidence interval, 0.10-0.69). The survival of patients with PS improvement postcryotherapy was longer than that of patients without PS improvement (median, 406 versus 106 days; log-rank test, P=0.02; hazard ratio, 0.28; 95{\%} confidence interval, 0.10-0.81). Cryotherapy is a feasible treatment for MEM. With better PS after cryotherapy, further chemotherapy becomes possible for patients to improve survival when MEM caused dyspnea and poor PS.",
author = "Fang, {Yueh Fu} and Hsieh, {Meng Heng} and Wang, {Tsai Yu} and Lin, {Horng Chyuan} and Yu, {Chih Teng} and Chou, {Chun Liang} and Lin, {Shu Min} and Kuo, {Chih Hsi} and Chung, {Fu Tsai}",
year = "2014",
month = "1",
day = "1",
doi = "10.1155/2014/369739",
language = "English",
volume = "2014",
journal = "The Scientific World Journal",
issn = "2356-6140",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Removal of endobronchial malignant mass by cryotherapy improved performance status to receive chemotherapy

AU - Fang, Yueh Fu

AU - Hsieh, Meng Heng

AU - Wang, Tsai Yu

AU - Lin, Horng Chyuan

AU - Yu, Chih Teng

AU - Chou, Chun Liang

AU - Lin, Shu Min

AU - Kuo, Chih Hsi

AU - Chung, Fu Tsai

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Although malignant endobronchial mass (MEM) has poor prognosis, cryotherapy is reportedly a palliative treatment. Clinical data on postcryotherapy MEM patients in a university-affiliated hospital between 2007 and 2011 were evaluated. Survival curve with or without postcryotherapy chemotherapy and performance status (PS) improvement of these subjects were analyzed using the Kaplan-Meier method. There were 59 patients (42 males), with median age of 64 years (range, 51-76, and median performance status of 2 (interquartile range [IQR], 2-3). Postcryotherapy complications included minor bleeding (n=12) and need for multiple procedures (n=10), while outcomes were relief of symptoms (n=51), improved PS (n=45), and ability to receive chemotherapy (n=40). The survival of patients with chemotherapy postcryotherapy was longer than that of patients without such chemotherapy (median, 534 versus 106 days; log-rank test, P=0.007; hazard ratio, 0.25; 95% confidence interval, 0.10-0.69). The survival of patients with PS improvement postcryotherapy was longer than that of patients without PS improvement (median, 406 versus 106 days; log-rank test, P=0.02; hazard ratio, 0.28; 95% confidence interval, 0.10-0.81). Cryotherapy is a feasible treatment for MEM. With better PS after cryotherapy, further chemotherapy becomes possible for patients to improve survival when MEM caused dyspnea and poor PS.

AB - Although malignant endobronchial mass (MEM) has poor prognosis, cryotherapy is reportedly a palliative treatment. Clinical data on postcryotherapy MEM patients in a university-affiliated hospital between 2007 and 2011 were evaluated. Survival curve with or without postcryotherapy chemotherapy and performance status (PS) improvement of these subjects were analyzed using the Kaplan-Meier method. There were 59 patients (42 males), with median age of 64 years (range, 51-76, and median performance status of 2 (interquartile range [IQR], 2-3). Postcryotherapy complications included minor bleeding (n=12) and need for multiple procedures (n=10), while outcomes were relief of symptoms (n=51), improved PS (n=45), and ability to receive chemotherapy (n=40). The survival of patients with chemotherapy postcryotherapy was longer than that of patients without such chemotherapy (median, 534 versus 106 days; log-rank test, P=0.007; hazard ratio, 0.25; 95% confidence interval, 0.10-0.69). The survival of patients with PS improvement postcryotherapy was longer than that of patients without PS improvement (median, 406 versus 106 days; log-rank test, P=0.02; hazard ratio, 0.28; 95% confidence interval, 0.10-0.81). Cryotherapy is a feasible treatment for MEM. With better PS after cryotherapy, further chemotherapy becomes possible for patients to improve survival when MEM caused dyspnea and poor PS.

UR - http://www.scopus.com/inward/record.url?scp=84908346084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908346084&partnerID=8YFLogxK

U2 - 10.1155/2014/369739

DO - 10.1155/2014/369739

M3 - Article

C2 - 25383370

AN - SCOPUS:84908346084

VL - 2014

JO - The Scientific World Journal

JF - The Scientific World Journal

SN - 2356-6140

M1 - 369739

ER -